Feature

Small victories add up to paradigm shifts for hard-to-treat tumors


 

Since the “war on cancer” was declared in the 1970s, our view of cancer has evolved to an array of different diseases requiring individual battles. Many have been hard-fought, with even minor improvements in patient survival proving extremely challenging. Here we describe how recent developments are beginning to change the narrative for some of these hard-to-treat tumor types.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Endoscopic mucosal resection proves effective, durable for Barrett’s-associated neoplasia
MDedge Hematology and Oncology
Antibiotic bowel prep significantly reduces colon surgery infections
MDedge Hematology and Oncology
Palliative tumor removal extends survival
MDedge Hematology and Oncology
Docetaxel/oxaliplatin/5-fluorouracil effective in treatment of advanced gastric cancer
MDedge Hematology and Oncology
More activity, less television prolongs life in colorectal Ca
MDedge Hematology and Oncology
Immunosuppression not tied to subsequent cancer in IBD with cancer history
MDedge Hematology and Oncology
New agent extends progression-free survival in advanced pancreatic cancer
MDedge Hematology and Oncology
FDA approves lanreotide for GEP-NETs after priority review
MDedge Hematology and Oncology
A feasibility study of dignity therapy in patients with stage IV colorectal cancer actively receiving second-line chemotherapy
MDedge Hematology and Oncology
Ramucirumab for advanced gastric or GEJ adenocarcinoma in previously treated patients with disease progression
MDedge Hematology and Oncology